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Although almost two decades of study point to a central role for aberrant ErbB2 activation in breast cancer, many cellular and 
biochemical mechanisms underlying ErbB2-induced tumor initiation and progression remain to be resolved. A study by Guo 
et al. published recently in Cell indicates that the signaling function of β4 integrin actively contributes to the initiation, growth, 
and invasion of ErbB2-induced mammary tumors in transgenic mice by promoting the activation of c-Jun and STAT3. These 
observations offer novel mechanistic insight into ErbB2 action and highlight the notion that ErbB2 co-opts the functions of 
other signaling proteins to elicit tumor progression.93cancer cell august 2006 
Overexpression of the ErbB2 (HER2/neu) 
receptor tyrosine kinase is observed in a 
variety of solid tumor types, including 20%–
30% of breast tumors. Overexpression 
correlates with poor patient prognosis 
and resistance to some therapies. In vitro, 
expression of a constitutively active point 
mutant of ErbB2 is sufficient to mediate 
the transformation of cultured cells, sug-
gesting that aberrant kinase activation is 
sufficient to initiate tumorigenic processes. 
Likewise, expression of an activated form 
in the mammary epithelium of transgenic 
mice gives rise to the rapid emergence of 
invasive tumors, pointing to a central role 
for ErbB2 activation in breast cancer malig-
nancy. Coupled with reports that ErbB2 
overexpression is sufficient to activate its 
tyrosine kinase activity, such observations 
have prompted the development of strate-
gies to interfere with ErbB2 activity in breast 
tumors. Indeed, the humanized anti-ErbB2 
monoclonal antibody Herceptin has been in 
clinical use for over a half dozen years, and 
other therapies are under development.
While it is clear that aberrant ErbB2 
activation actively contributes to the gen-
esis and progression of breast tumors, 
cellular and biochemical mechanisms underlying ErbB2-mediated proliferation 
and invasion remain to be fully elucidat-
ed. Of particular interest are the mecha-
nisms connecting activated ErbB2 to the 
breakdown of mammary epithelial cell-cell 
interactions. ErbB2 activation dissolves 
interepithelial cell interactions mediated 
by tight junctions or by adherens junctions 
through E-cadherin, leading to a loss of cell 
polarity and the initiation of invasion. An 
insightful study by Guo et al. (2006) points 
to a key role for cellular signaling mediated 
by β4 integrin in ErbB2-mediated prolifera-
tion and invasiveness of breast tumor cells 
and underscores an unappreciated role for 
STAT3 signaling in mediating the loss of 
mammary epithelial adhesion.
Hemidesmosomal α6β4 integrin con-
tributes to the anchoring of mammary epi-
thelial cells to the basement membrane 
through its intracellular interactions with 
the cytoskeleton and extracellular interac-
tions with the matrix component laminin-
5. Several studies suggest that the large 
intracellular domain of the β4 subunit is 
also involved in cellular signaling. For 
example, expression of β4 integrin in β4-
deficient cultured breast cancer cells aug-
ments cellular invasive properties (Shaw et al., 1997). This effect requires the β4 
intracellular domain and is suppressed by 
inhibitors of PI3 kinase activity, suggesting 
that β4 signaling to the PI3 kinase pathway 
augments the invasiveness of these cells. 
Moreover, blocking antibodies to either α6 
or β4 integrin subunits suppress the forma-
tion of apoptosis-resistant acinar structures 
in Matrigel by mammary epithelial cells 
(Weaver et al., 2002), suggesting a role 
for β4-mediated cellular polarity in mediat-
ing antiapoptotic signaling. Finally, β4 has 
been demonstrated to physically interact 
with ErbB2 in some cultured breast tumor 
cells, and the two proteins synergize in 
promoting cellular proliferation and inva-
sion (Falcioni et al., 1997). Taken together, 
these and other in vitro studies strongly 
point to a potential role for β4 signaling in 
promoting breast tumor progression.
To examine the role of β4 integrin sig-
naling in ErbB2-induced mammary tumors 
in vivo, Guo et al. employed a knockin 
mouse where expression of the endoge-
nous β4 gene was replaced with a variant 
(called 1355T) lacking the carboxy terminal 
?450 amino acids. This form is capable of 
interacting with laminin-5 and the keratin 
cytoskeleton, thus maintaining the ability 
	 p r e v i e w sFigure 1. activated ErbB2 co-opts β4 integrin to promote mammary tumor progression
a: In normal mammary epithelium, basally localized ErbB2 and β4 signal minimally. 
B: activated ErbB2 forms a complex with β4 integrin and a src family kinase (sFK), leading to the tyrosine 
phosphorylation (asterisks) of all three components and signaling to c-Jun and stat3. c-Jun signaling 
mediates cellular proliferation, while stat3 signaling leads to cell-cell junction breakdown and the 
initiation of invasion.to mediate adhesion, but lacks five tyrosine 
phosphorylation sites (Nikolopoulos et al., 
2004). Female knockin animals exhibit nor-
mal gross mammary gland morphogenesis 
and nursing, suggesting that β4 signaling 
does not play a major role in mammary 
gland development.
These mice were crossed into a 
mouse model of mutationally activat-
ed ErbB2-induced mammary tumors 
(Dankort et al., 2001), and the properties 
of tumors expressing the 1355T variant 
were compared with tumors expressing 
wild-type β4 integrin. Loss of the signaling 
domain delayed the median time for tumor 
onset and inhibited tumor multiplicity and 
size, suggesting that signaling by integrin 
β4 facilitates both ErbB2-induced tumor 
formation and growth. Moreover, tumors 
expressing the 1355T form exhibited 
significantly fewer lung metastases, sug-
gesting that β4 signaling also facilitates 
ErbB2-mediated tumor invasion and 
metastasis. These observations confirm 
previous reports that β4 integrin may syn-
ergize with ErbB2 in augmenting mam-
mary epithelial tumorigenic properties and 
focus attention on the signaling functions 
of the integrin.
Interestingly, histological analysis of 
tumors at various stages of development 
began to reveal mechanistic insights into 
the role of β4 signaling in mammary tumor 
progression. In general, tumors from mice 
expressing the 1355T form tended to be 
more differentiated, characterized by a 
glandular appearance, while tumors from 
mice expressing wild-type β4 were poorly 
94 differentiated solid masses. Tumors from 
mice expressing wild-type β4 exhibited 
a higher degree of proliferation and a 
lower degree of apoptosis than tumors 
from 1355T animals. Moreover, staining 
for basal plasma membrane and tight 
junction markers pointed to a loss of cell 
polarity in tumors from wild-type β4 mice 
but less so in tumors from 1355T mice. 
Importantly, treatment of cultured cells 
from the wild-type β4 tumors with Iressa, 
a small molecule inhibitor of EGF receptor 
that can also act toward ErbB2, restored 
polarity, suggesting that β4 effects on cell 
polarity were the outcome of signaling 
events rather than secondary mutations 
in the tumors. Collectively, these observa-
tions suggest that ErbB2 and β4 integrin 
cooperatively signal the disruption of epi-
thelial adhesion and polarity, contributing 
to tumor progression by promoting epithe-
lial invasiveness.
To elucidate the molecular mecha-
nisms by which β4 integrin and ErbB2 
might cooperate in signaling tumor pro-
gression, Guo et al. developed an in vitro 
knockin system, where expression of the 
endogenous mouse β4 gene in ErbB2-
induced tumor cells was suppressed by 
RNAi and replaced with either wild-type 
or 1355T human integrin β4. This system 
recapitulated most phenotypic aspects 
of the in vivo tumors, including the aug-
mentation of cellular proliferation and the 
disruption of adhesion in cells expressing 
wild-type β4 relative to 1355T. Through a 
series of coimmunoprecipitation, phos-
phorylation, and inhibitor studies, the authors developed a model whereby the 
β4 signaling domain assembles a ternary 
complex of ErbB2, a src family kinase, and 
β4 integrin. Thus, its signaling domain per-
mits β4 integrin to interact with ErbB2 and 
expand its signaling potential.
The abundance of phosphorylated 
forms of the transcriptional regulators c-
Jun and STAT3 in cells expressing wild-
type β4 relative to 1355T suggested that 
these factors could play central roles in 
mediating synergistic cellular responses 
to the ErbB2/β4 complex in cells express-
ing wild-type β4. Indeed, inhibition of c-
Jun function in cells suppressed tumor 
cell proliferation in vitro and tumorigenicity 
but was unable to restore the assembly 
of cell-cell junctions or inhibit invasion. 
Conversely, inhibition of STAT3 function 
restored assembly of tight and adherens 
junctions and inhibited invasion but had 
little impact on proliferation or tumorige-
nicity. In summary, the signaling domain of 
β4 integrin allows its physical association 
with activated ErbB2, leading to the acti-
vation of c-Jun and STAT3, and resulting 
in the independent stimulation of tumor 
cell proliferation and invasion (Figure 1).
These studies provide novel insight 
into processes leading to the breakdown 
of cellular adhesion upon ErbB2 activation. 
The ErbB2/β4 complex activates STAT3, 
presumably to regulate the expression 
of genes that contribute to the structural 
integrity of cell-cell junctions, particularly 
tight junctions. This is consistent with a 
very recent report that STAT3 activation 
downstream of the EGFR is necessary 
but not sufficient for prostate tumor cell 
migration and invasion (Zhou et al., 2006), 
suggesting a common role for STAT3 
involvement in growth factor receptor-
induced invasiveness. These observations 
in turn point to the ErbB2/β4 complex and 
activated STAT3 as potential targets for 
therapeutic suppression of breast tumor 
progression.
These studies additionally under-
score the concept that otherwise qui-
escent signaling molecules may be 
co-opted by ErbB2 in promoting tumor 
progression. While β4 signaling contribu-
tion to normal mouse mammary gland 
development is minimal, it is clearly 
required to fully promote the malignancy 
of tumors in an activated ErbB2 mouse 
model. It will be interesting to determine 
whether the functions of other signaling-
related proteins such as ErbB3, CD44, or 
Muc4 are similarly recruited by ErbB2 to 
promote the initiation or progression of cancer cell august 2006
	 p r e v i e w smammary tumors. Again, the necessity 
of such accessory proteins in tumor pro-
gression offers novel avenues for thera-
peutic intervention.
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von Hippel-Lindau disease (OMIM 193300) 
is a rare hereditary cancer syndrome that 
is characterized by the development of 
hypervascular tumors in multiple, and yet 
specific, organs, including the cerebellum, 
retina, adrenal gland, and kidney. VHL 
disease is caused by the inheritance of 
a faulty VHL gene, and the tumors arise 
when the remaining wild-type VHL allele 
is lost or inactivated via mutation, deletion, 
or promoter methylation in a susceptible 
cell. Biallelic inactivation of VHL has also 
been associated with the development of 
sporadic clear cell renal cell carcinoma 
(CC-RCC), the most common form of 
kidney cancer (Kaelin, 2002).
pVHL is a substrate-recruiting compo-
nent of an E3 ubiquitin ligase called ECV 
(Elongins/Cul2/pVHL) that is structurally 
and functionally analogous to the SCF 
(Skp1/Cdc53/F box protein) complex. 
Crystal structure of the pVHL/elongin B/
elongin C complex revealed two functional 
domains on pVHL: α and β (Stebbins et 
al., 1999). The α domain binds elongin C, 
which acts as a bridge connecting pVHL to 
the scaffold component Cul2, which binds 
Rbx1 and a cognate E2 ubiquitin-conju-
gating enzyme, Cdc34 or UbcH5. The β 
domain acts as a substrate-docking site. 
The majority of tumor-associated VHL 
mutations map to the surface residues 
on either domain, suggesting that these 
pVHL’s kryptonite: E2-
E2-EPF ubiquitin carrier protein (UCP) is a 
targeted for destruction by the proteasom
oncogenesis, but a physiologic target of U
al. identified von Hippel-Lindau (VHL) tum
for ubiquitin-mediated destruction, as a bo
role for UCP in cancer development.Selected reading
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To date, several cellular proteins have 
been identified as pVHL binding proteins 
that are subjected to ECV-dependent 
ubiquitylation. However, the most con-
vincing substrate that continues to shed 
significant insight into the tumor sup-
pressor function of pVHL is HIFα (see 
Figure 1). HIF is a major heterodimeric 
transcription factor consisting of α and β 
subunits that transactivates 60 or more 
hypoxia-inducible genes, including vas-
cular endothelial growth factor (VEGF; 
also known as vascular permeability fac-
tor), erythropoietin (EPO), and glucose 
transporter-1 (GLUT1) to promote angio-
genesis, oxygen-carrying erythrocyte 
production, and anaerobic metabolism, 
respectively, in adaptation to compro-
mised oxygen availability. While the HIFβ 
subunit (also known as aryl-hydrocarbon 
receptor nuclear translocator [ARNT]) is 
abundantly expressed irrespective of oxy-
gen tension, the HIFα subunit is oxygen 
labile. In the presence of oxygen, HIFα is 
hydroxylated on conserved prolines within 
the oxygen-dependent degradation (ODD) 
domain by prolyl hydroxylase domain-con-
taining enzymes (PHDs). Prolyl hydroxyl-
ation is both necessary and sufficient for 
the binding of HIFα by pVHL and subse-
quent ubiquitylation via ECV. Accordingly, 
EPF UCP
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CP has not been identified. In a recent rep
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hypoxia or mutation in pVHL leads to the 
stabilization of HIFα. HIFα then dimerizes 
with HIFβ to form an active transcriptional 
complex, which engages the 5′-RCGTG-
3′ hypoxia-responsive elements (HREs) 
within the promoter/enhancer of hypoxia-
talyzes the ligation of ubiquitin to proteins 
n cancers, suggesting its involvement in 
ort published in Nature Medicine, Jung et 
 subunit of hypoxia-inducible factor (HIF) 
 a potential pVHL-HIF pathway-dependent 
Figure 1. the uCP-pVHL-HIF pathway in cancer
see text for details. eBC, elongins B and C; N8, 
NEDD8; ub, ubiquitin; OH, hydroxyl group.
